Background: We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors. Methods: This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A, who had received proton-based SBRT to one to four liver metastases from solid tumors. Treatment comprised 30 to 50 Gray equivalent (GyE) in five fractions based on the effective volume of liver irradiated. Sample size was calculated to determine if local control (LC) at one year was greater than 70%. The cumulative incidence of local failure was used to estimate LC. The association of tumor characteristics, including genetic alterations in common cancer genes such as BRAF, EGFR, HER2, KRAS, NRAS, PIK3CA, and TP53 with local tumor control, was assessed. All statistical tests were two-sided. Results: Eighty-nine patients were evaluable (colorectal, n = 34; pancreatic, n = 13; esophagogastric, n = 12; other, n = 30). Median tumor size was 2.5 cm (range = 0.5-11.9 cm). Median dose was 40 GyE (range = 30-50 GyE), and median follow-up was 30.1 months (range = 14.7-53.8 months). There was no grade 3 to 5 toxicity. Median survival time was 18.1 months. The one- and three-year LC rates were 71.9% (95% confidence limit [CL] = 62.3% to 80.9%) and 61.2% (95% CL = 50.8% to 71.8%), respectively. For large tumors (≥6 cm), one-year LC remained high at 73.9% (95% CL = 54.6% to 89.8%). Mutation in the KRAS oncogene was the strongest predictor of poor LC (P = .02). Tumor with both mutant KRAS and TP53 were particularly radioresistant, with a one-year LC rate of only 20.0%, compared with 69.2% for all others (P = .001). Conclusions: We report the largest prospective evaluation to date of liver SBRT for hepatic metastases, and the first with protons. Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor LC, stressing the need for tumor genotyping prior to SBRT and treatment intensification in this patient subset.
Background: We evaluated the efficacy and safety of risk-adapted, proton-based stereotactic body radiation therapy (SBRT) for liver metastases from solid tumors. Methods: This single-arm phase II single institutional study (NCT01239381) included patients with limited extrahepatic disease, 800 mL or greater of uninvolved liver, and no cirrhosis or Child-Pugh A, who had received proton-based SBRT to one to four liver metastases from solid tumors. Treatment comprised 30 to 50 Gray equivalent (GyE) in five fractions based on the effective volume of liver irradiated. Sample size was calculated to determine if local control (LC) at one year was greater than 70%. The cumulative incidence of local failure was used to estimate LC. The association of tumor characteristics, including genetic alterations in common cancer genes such as BRAF, EGFR, HER2, KRAS, NRAS, PIK3CA, and TP53 with local tumor control, was assessed. All statistical tests were two-sided. Results: Eighty-nine patients were evaluable (colorectal, n = 34; pancreatic, n = 13; esophagogastric, n = 12; other, n = 30). Median tumor size was 2.5 cm (range = 0.5-11.9 cm). Median dose was 40 GyE (range = 30-50 GyE), and median follow-up was 30.1 months (range = 14.7-53.8 months). There was no grade 3 to 5 toxicity. Median survival time was 18.1 months. The one- and three-year LC rates were 71.9% (95% confidence limit [CL] = 62.3% to 80.9%) and 61.2% (95% CL = 50.8% to 71.8%), respectively. For large tumors (≥6 cm), one-year LC remained high at 73.9% (95% CL = 54.6% to 89.8%). Mutation in the KRAS oncogene was the strongest predictor of poor LC (P = .02). Tumor with both mutant KRAS and TP53 were particularly radioresistant, with a one-year LC rate of only 20.0%, compared with 69.2% for all others (P = .001). Conclusions: We report the largest prospective evaluation to date of liver SBRT for hepatic metastases, and the first with protons. Protons were remarkably well tolerated and effective even for metastases that were 6 cm or larger. KRAS mutation is a strong predictor of poor LC, stressing the need for tumor genotyping prior to SBRT and treatment intensification in this patient subset.
Authors: Christina Wu; Terence M Williams; Evan Wuthrick; Ryan Robb; Amy Webb; Lai Wei; Wei Chen; Sameh Mikhail; Kristen K Ciombor; Dana B Cardin; Cynthia Timmers; Somashekar G Krishna; Mark Arnold; Alan Harzman; Sherif Abdel-Misih; Sameek Roychowdhury; Tanios Bekaii-Saab Journal: Clin Cancer Res Date: 2020-04-06 Impact factor: 12.531
Authors: Thomas J George; Aaron J Franke; A Bapsi Chakravarthy; Prajnan Das; Arvind Dasari; Bassel F El-Rayes; Theodore S Hong; Timothy J Kinsella; Jerome C Landry; James J Lee; Arta M Monjazeb; Samuel A Jacobs; David Raben; Osama E Rahma; Terence M Williams; Christina Wu; C Norman Coleman; Bhadrasain Vikram; Mansoor M Ahmed Journal: Cancer Date: 2019-04-24 Impact factor: 6.860
Authors: Theodore S Hong; Eliezer M Van Allen; Sophia C Kamran; Jochen K Lennerz; Claire A Margolis; David Liu; Brendan Reardon; Stephanie A Wankowicz; Emily E Van Seventer; Adam Tracy; Jennifer Y Wo; Scott L Carter; Henning Willers; Ryan B Corcoran Journal: Clin Cancer Res Date: 2019-06-28 Impact factor: 12.531
Authors: Alex R Coffman; Daniel C Sufficool; Joseph I Kang; Chung-Tsen Hsueh; Sasha Swenson; Patrick Q McGee; Gayathri Nagaraj; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2021-08
Authors: Ronik S Bhangoo; Trey C Mullikin; Jonathan B Ashman; Tiffany W Cheng; Michael A Golafshar; Todd A DeWees; Jedediah E Johnson; Satomi Shiraishi; Wei Liu; Yanle Hu; Kenneth W Merrell; Michael G Haddock; Sunil Krishnan; William G Rule; Terence T Sio; Christopher L Hallemeier Journal: Adv Radiat Oncol Date: 2021-03-02
Authors: Patrick H Dinkelborg; Meng Wang; Liliana Gheorghiu; Joseph M Gurski; Theodore S Hong; Cyril H Benes; Dejan Juric; Rachel B Jimenez; Kerstin Borgmann; Henning Willers Journal: Breast Cancer Res Treat Date: 2019-01-03 Impact factor: 4.872
Authors: Joseph I Kang; Daniel C Sufficool; Chung-Tsen Hsueh; Andrew J Wroe; Baldev Patyal; Mark E Reeves; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2019-02
Authors: Ali Ajdari; Yunhe Xie; Christian Richter; Maximilian Niyazi; Dan G Duda; Theodore S Hong; Thomas Bortfeld Journal: JCO Clin Cancer Inform Date: 2021-03